CSPC Pharmaceutical Group’s Stock Price Falls to 7.04 HKD, Recording a 1.12% Decrease

CSPC Pharmaceutical Group (1093)

7.04 HKD -0.08 (-1.12%) Volume: 581.24M

CSPC Pharmaceutical Group’s stock price stands at 7.04 HKD, experiencing a slight decline of -1.12% this trading session with an active trading volume of 581.24M. Year-to-date, the stock has seen a moderate decrease of -3.03%, reflecting its volatile performance in the pharmaceutical market.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group‘s stock price saw significant movements following the news of AstraZeneca signing a $1.92 billion licensing deal with the Hong Kong-listed company. AstraZeneca paid CSPC $100 million for a preclinical heart disease drug, setting the stage for potential combinations and intensifying competition with Lilly. This deal expands AstraZeneca’s cardiovascular disease prospects, particularly in the realm of lipid-lowering therapies. With AstraZeneca investing heavily in this partnership, the pharmaceutical giant is positioning itself for future growth in the cholesterol drug market.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group Limited appears to have a positive long-term outlook. With high scores in Dividend and Value, the company is seen as financially stable and offering good returns to investors. Additionally, strong scores in Growth and Resilience indicate that CSPC Pharmaceutical Group is well-positioned for future expansion and able to weather market challenges. While the Momentum score is slightly lower, the overall outlook for the company remains promising.

CSPC Pharmaceutical Group Limited, known for its production and sale of pharmaceutical products such as vitamin C, antibiotics, and generic drugs, is also involved in the development of innovative medications. With favorable Smartkarma Smart Scores in key areas, the company demonstrates a commitment to financial health, growth, and adaptability in the competitive pharmaceutical industry. Investors may find CSPC Pharmaceutical Group to be a reliable option for long-term investment opportunities.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma